Journal article

Alzheimer's Disease: A Journey (f)rom Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies-Gains from AIBL and DIAN Cohort Studies

Ralph N Martins, Victor Villemagnen, Hamid R Sohrabi, Pratishtha Chatterjee, Tejal M Shah, Giuseppe Verdile, Paul Fraser, Kevin Taddei, Veer B Gupta, Stephanie R Rainey-Smith, Eugene Hone, Steve Pedrini, Wei Ling Lim, Ian Martins, Shaun Frost, Sunil Gupta, Sid O'Bryant, Alan Rembach, David Ames, Kathryn Ellis Show all

JOURNAL OF ALZHEIMERS DISEASE | IOS PRESS | Published : 2018

Abstract

Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group in Western Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the journey from the discovery of the Aβ peptide in Alzheimer's disease (AD) ..

View full abstract